Literature DB >> 25252716

CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.

James M Hughes, Beatrice Salvatori, Federico M Giorgi, Irene Bozzoni, Alessandro Fatica1.   

Abstract

CCAAT/enhancer-binding protein-α (CEBPA) is a critical regulator of myeloid differentiation. Disruption of CEBPA function contributes to the development of acute myeloid leukemia (AML). CEBPA regulates a large number of protein coding genes of which several were shown to contribute to CEBPA function. In this study, we expand the analysis of CEBPA transcriptional targets to the newly identified class of long non-coding RNAs. We show that lncRNAs are a main component of the transcriptional program driven by C/EBPα and that many of these are also induced during granulocytic differentiation of AML cell lines supporting their relevance in proliferation arrest and differentiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25252716      PMCID: PMC4177583          DOI: 10.1186/s13045-014-0069-1

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


To the Editor

LncRNAs participate in multiple networks controlling cell differentiation and development [1], with their expression already associated with cancer and several disorders [2]. To what degree C/EBPα regulates the expression of lncRNAs is still largely unknown. To investigate the effect of C/EBPα on the expression of lncRNAs we utilized the K562 AML cell line carrying a stable and Tet-on inducible CEBPA allele (Additional file 1 and Additional file 2: Figure S1). K562 cells lack endogenous C/EBPα and restoration of its expression induces proliferation arrest and granulocytic differentiation [3] (Additional file 1 and Additional file 2: Figure S1). Based on the expression of known C/EBPα transcriptional targets, we selected RNA extracted from 48 hours of induction (K562-C/EBPα) together with RNA extracted from control-induced cells (K562-CTR). Gene expression profiling was performed using the Agilent Whole Human Genome Oligo 8x60K v2 Microarrays from 4 biological replicates for each sample (Figure 1A). We identified 4605 mRNAs (2643 induced and 1962 repressed) and 930 lncRNAs (600 induced and 330 repressed) with significant differential expression (fold change ≥ 2 and p-value ≤ 0.05) between C/EBPα- and CTR- induced cells (Figure 1B and Additional file 1, Additional files 3 and 4: Tables S1 and S2). Appropriate expression patterns of many known coding transcriptional targets of C/EBPα confirmed the reliability of our gene expression analysis (Additional file 1 and Additional file 2: Figure S1). Gene set enrichment and Gene ontology analysis confirmed significant enrichment of known C/EBPα targets [4] (NES = 7.97, p = 1.65×10−15), coupled with down-regulation of cell cycle genes and upregulation of granulocytic differentiation pathways (Figure 2). Notably, we found the E2F1 motif to be negatively enriched in the promoters of C/EBPα repressed genes (NES = −7.18, p = 7.06×10−13), confirming the known role of C/EBPα in repressing E2F1 activity (Additional file 5: Figure S2). Expression of differentially induced lncRNAs was further validated by qRT-PCR in K562 -C/EBPα and -CTR cells (Figure 2A). When applicable, official lncRNA reference names were utilized. Otherwise, we refer to as lnc-CUs (lncRNA-C/EBPα-up-regulated) and lnc-DCs (lncRNA-C/EBPα down-regulated) for induced and repressed lncRNAs, respectively (Additional file 1 and Additional file 6: Table S3).
Figure 1

LncRNAs are a component of the C/EBPα-regulated transcriptional network in AML. (A) Experimental pipeline for identification of C/EBPα-regulated lncRNAs. See text and Additional file 1 for details (B) Heat maps of median centered log2 fold change values from microarray analysis of mRNAs and lncRNAs with significant differential expression (fold change ≥ 2 and adjusted p-value ≤ 0.05). Exact values are provided in Additional files 3 and 4: Table S1 and Table S2. Presence of CEBPB or CEBPD binding sites is indicated on the side of each heat maps.

Figure 2

Validation of selected lncRNAs. (A) Quantitative real time RT-PCR analysis of selected lncRNAs in K562-C/EBPα treated for 48 hours with doxycycline. Values were compared to K562-CTR cells treated for the same time and normalized with HPRT mRNA. The histograms represent the log2 fold change of the relative expression ± SEM from three replicates. TCONS names and chromosomal positions are provided as Additional file 6: Table S3. (B) Quantitative real time RT-PCR analysis of selected lncRNAs in NB4 cells treated for 72 hours with all-trans-retinoic acid (ATRA). Values were compared to untreated NB4 cells and normalized with HPRT mRNA. The histograms represent the log2 fold change of the relative expression ± SEM from three replicates.

LncRNAs are a component of the C/EBPα-regulated transcriptional network in AML. (A) Experimental pipeline for identification of C/EBPα-regulated lncRNAs. See text and Additional file 1 for details (B) Heat maps of median centered log2 fold change values from microarray analysis of mRNAs and lncRNAs with significant differential expression (fold change ≥ 2 and adjusted p-value ≤ 0.05). Exact values are provided in Additional files 3 and 4: Table S1 and Table S2. Presence of CEBPB or CEBPD binding sites is indicated on the side of each heat maps. Validation of selected lncRNAs. (A) Quantitative real time RT-PCR analysis of selected lncRNAs in K562-C/EBPα treated for 48 hours with doxycycline. Values were compared to K562-CTR cells treated for the same time and normalized with HPRT mRNA. The histograms represent the log2 fold change of the relative expression ± SEM from three replicates. TCONS names and chromosomal positions are provided as Additional file 6: Table S3. (B) Quantitative real time RT-PCR analysis of selected lncRNAs in NB4 cells treated for 72 hours with all-trans-retinoic acid (ATRA). Values were compared to untreated NB4 cells and normalized with HPRT mRNA. The histograms represent the log2 fold change of the relative expression ± SEM from three replicates. In order to annotate the presence of putative C/EBPα binding sites in the promoter of differentially expressed genes, we used previously generated ChIP data sets for CEBPB (C/EBPβ) and CEBPD (C/EBPδ) in K562 cells [5], which exhibit identical DNA-binding specificities with C/EBPα [6]. We found several coding and non-coding differentially expressed genes bound by either CEBPB or CEBPD in their putative promoter region within a distance of −5 kb from the TSS (Figure 1B and Additional file 1, Additional file 7: Figure S3, Additional file 8: Table S4, Additional file 9: Table S5, Additional file 10: Table S6 and Additional file 11: Table S7). Different AML cell lines are widely used to study the block of differentiation in AML because they can be differentiated in mature and functional myeloid cells by treatment with specific agents. Thus, we analysed the expression of selected lncRNAs in NB4 cells, which are able to undergo granulocytic differentiation by treatment with all-trans retinoic acid (ATRA) [7]. Notably, the majority of validated C/EBPα-induced lncRNAs in K562 are also significantly upregulated by ATRA in NB4 (21 out of 26), suggesting that they may play a role in the differentiation process (Figure 2B). Nevertheless, upon validated lncRNAs repressed by C/EBPα treatment in K562, 6 out of 8 showed opposite trend while 2 were not significantly expressed in NB4 (data not shown). This behaviour still remains to be explained and extended to the study of more lncRNAs in NB4 cell line: we speculate it could be due to silencing of diverse cellular settings between K562 and NB4 cell lines. In summary, this study shows that lncRNAs are a main component of the transcriptional program driven by C/EBPα. We identified more than 900 lncRNAs regulated by C/EBPα in K562. We confirmed that the majority of these are also induced during granulocytic differentiation of AML cell lines supporting their relevance in proliferation arrest and differentiation. How many of the lncRNAs identified in this study are directly involved in regulating differentiation programmes of AML is an interesting question that warrants further investigations. Moreover, regardless of function, this work indicates that changes in lncRNAs expression might also have diagnostic applications in AML with CEBPA mutations.
  7 in total

Review 1.  Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.

Authors:  M J Roussel; M Lanotte
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

Review 2.  The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation.

Authors:  Junichi Tsukada; Yasuhiro Yoshida; Yoshihiko Kominato; Philip E Auron
Journal:  Cytokine       Date:  2011-01-22       Impact factor: 3.861

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation.

Authors:  Sigal Tavor; Dorothy J Park; Sigal Gery; Peter T Vuong; Adrian F Gombart; H Phillip Koeffler
Journal:  J Biol Chem       Date:  2003-09-29       Impact factor: 5.157

Review 5.  Long noncoding RNAs: cellular address codes in development and disease.

Authors:  Pedro J Batista; Howard Y Chang
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

6.  Genome-wide mapping of in vivo protein-DNA interactions.

Authors:  David S Johnson; Ali Mortazavi; Richard M Myers; Barbara Wold
Journal:  Science       Date:  2007-05-31       Impact factor: 47.728

Review 7.  Long non-coding RNAs: new players in cell differentiation and development.

Authors:  Alessandro Fatica; Irene Bozzoni
Journal:  Nat Rev Genet       Date:  2013-12-03       Impact factor: 53.242

  7 in total
  11 in total

1.  CEBPA-mediated upregulation of the lncRNA PLIN2 promotes the development of chronic myelogenous leukemia via the GSK3 and Wnt/β-catenin signaling pathways.

Authors:  Chengming Sun; Shuping Luan; Guili Zhang; Na Wang; Huiyuan Shao; Caifu Luan
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 2.  Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia.

Authors:  Mariangela Morlando; Monica Ballarino; Alessandro Fatica
Journal:  Front Med (Lausanne)       Date:  2015-04-14

3.  Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets.

Authors:  Roshan Fatima; Vijay Suresh Akhade; Debosree Pal; Satyanarayana Mr Rao
Journal:  Mol Cell Ther       Date:  2015-06-12

Review 4.  Clinical significance of microRNAs in chronic and acute human leukemia.

Authors:  Chien-Hung Yeh; Ramona Moles; Christophe Nicot
Journal:  Mol Cancer       Date:  2016-05-14       Impact factor: 27.401

5.  C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.

Authors:  James M Hughes; Ivano Legnini; Beatrice Salvatori; Silvia Masciarelli; Marcella Marchioni; Francesco Fazi; Mariangela Morlando; Irene Bozzoni; Alessandro Fatica
Journal:  Oncotarget       Date:  2015-07-30

Review 6.  Long noncoding RNAs: pivotal regulators in acute myeloid leukemia.

Authors:  Shuyong Wei; Kankan Wang
Journal:  Exp Hematol Oncol       Date:  2016-12-12

7.  Expression levels of long non-coding RNAs are prognostic for AML outcome.

Authors:  Arvind Singh Mer; Johan Lindberg; Christer Nilsson; Daniel Klevebring; Mei Wang; Henrik Grönberg; Soren Lehmann; Mattias Rantalainen
Journal:  J Hematol Oncol       Date:  2018-04-07       Impact factor: 17.388

8.  The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA.

Authors:  Arianna Mangiavacchi; Melissa Sorci; Silvia Masciarelli; Simone Larivera; Ivano Legnini; Ilaria Iosue; Irene Bozzoni; Francesco Fazi; Alessandro Fatica
Journal:  Oncotarget       Date:  2016-09-13

9.  Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease.

Authors:  Lijing Sun; Meijun Si; Xinyan Liu; Jong Min Choi; Yanlin Wang; Sandhya S Thomas; Hui Peng; Zhaoyong Hu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-07-24       Impact factor: 12.910

10.  Epigenetic landscape analysis of lncRNAs in acute myeloid leukemia with DNMT3A mutations.

Authors:  Yu-Jun Dai; Fang Hu; Si-Yuan He; Yue-Ying Wang
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.